<DOC>
	<DOCNO>NCT00116389</DOCNO>
	<brief_summary>The purpose study assess 6-month survival rate safety talabostat gemcitabine patient stage IV adenocarcinoma pancreas .</brief_summary>
	<brief_title>Trial Talabostat Gemcitabine Patients With Stage IV Adenocarcinoma Pancreas</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Men woman age ≥18 year Histologically confirm metastatic ( stage IV ) adenocarcinoma pancreas Measurable disease define per RECIST Karnofsky Performance Status ≥50 Expected survival ≥12 week Provide write informed consent CNS metastases Prior treatment chemotherapy pancreatic cancer unless use radiosensitizer Radiation therapy &gt; 25 % bone marrow Clinically significant laboratory abnormality Any malignancy within 5 year immediately prior first dose study medication exception basal cell nonmetastatic squamous cell carcinoma skin , carcinoma insitu cervix The need chronic ( i.e. , &gt; 7 day ) oral intravenous corticosteroid therapy &gt; 10mg/day prednisone equivalent Any comorbidity condition , opinion investigator , may interfere assessment procedure protocol Patients within 28 day radiation therapy , biologic therapy , immunotherapy , investigational medication . All side effect prior treatment must resolve study entry . Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>cancer pancreas</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>pancreatic neoplasm</keyword>
	<keyword>Metastatic pancreatic cancer ( Stage IV )</keyword>
	<keyword>Stage IV Adenocarcinoma Pancreas</keyword>
</DOC>